Figure 3
From: Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment
Effects of ASO-T3 on gene expression in metabolic organs. (a,b) Browning markers (Ucp1, Pgc1a, Cidea, Cox7a1 and Cox8b) in inguinal white adipose tissue (iWAT). (c) Ucp1 expression in epididymal white adipose tissue (eWAT). (d) Expression of solute carrier family 6 member 8 (Scl6a8), glycine amidinotransferase (Gamt) and creatine kinase mitochondrial 2 (Ckmt2) in eWAT. (e) Expression of brown adipose tissue (BAT) gene markers. (f) Hepatic expression of thyroid hormone responsive genes deiodinase-1 (Dio1) and cholesterol 7alpha-hydroxylase (Cyp7a1). (g) Gluconeogenetic genes (G6pase, Pepck) and fatty acid synthesis genes (Acc1, Acc2 and Fas) in liver. (h,i) Expression of Mhc-b (h) and Mhc-a and Troponin (Trop) (i) in heart. (j) Expression of Serca1and Searca2a in muscle. NAT3: NNMT-ASO-T3; AAT3: ApoB-ASO-T3. n = 4–6 per group; *p < 0.05 vs control, §p = 0.07 vs control, #p < 0.05 vs T3.
